Related Experiment Videos
[Sepsis syndrome: progress and therapeutic perspectives]
1Département de médecine interne, CHUV, Lausanne.
Schweizerische Medizinische Wochenschrift
|May 16, 1992
Summary
Sepsis syndrome, a new clinical entity, requires aggressive treatment with antibiotics and hemodynamic support to prevent fatal septic shock. Experimental therapies targeting sepsis mediators show promise but are not yet established.
Area of Science:
- Critical care medicine
- Infectious diseases
- Pathophysiology
Context:
- High mortality rates associated with septic shock necessitate novel clinical approaches.
- Sepsis syndrome is defined as a distinct clinical entity requiring urgent intervention.
- Understanding the pathogenesis of sepsis and septic shock is crucial for developing effective treatments.
Purpose:
- To define sepsis syndrome as a clinical entity.
- To outline aggressive treatment strategies for sepsis syndrome, including antibiotic therapy and hemodynamic support.
- To review the status of experimental pharmacological and immunological interventions for sepsis and septic shock.
Summary:
- Sepsis syndrome is characterized by early signs of cardiocirculatory failure.
- Aggressive management involves broad-spectrum antibiotics and hemodynamic support (volume resuscitation, vasopressors, inotropic agents).
- Experimental therapies targeting inflammatory mediators and endotoxins have shown potential but require further validation.
Impact:
- Early recognition and aggressive treatment of sepsis syndrome can reduce mortality from septic shock.
- This approach aims to prevent the progression from sepsis to septic shock.
- Further research into novel immunomodulatory therapies may offer future treatment options.